Table 1 Baseline characteristics of study participants
From: Soluble receptor for advanced glycation end-products and progression of airway disease
All | Non-smokers | Smokers without COPD | Smokers with COPD | |
|---|---|---|---|---|
Subjects, n | 295 | 32 | 212 | 51 |
M/F | 161/134 | 10/22 | 109/103 | 42/9 |
Age years | 53.7 ± 9.3 | 56.0 ± 9.1 | 52.1 ± 8.8 | 58.9 ± 9.0 |
BMI | 27.0 ± 3.8 | 27.0 ± 3.9 | 26.9 ± 3.8 | 27.3 ± 3.9 |
Smoking status | ||||
Former smoker n (%) | 56 (19%) | 0 | 44 (21%) | 12 (23%) |
Current smoker n (%) | 207 (70%) | 0 | 168 (79%) | 39 (77%) |
Pack-years | 26.8 ± 16.7 | 0 | 28.3 ± 14.1 | 37.6 ± 14.1 |
Symptom | ||||
Only Cough n (%) | 17 (5.9%) | 0 (0%) | 13 (6.1%) | 4 (7.8%) |
Only Sputum n (%) | 58 (20.1%) | 6 (23.1%) | 47 (22.2%) | 5 (9.8%) |
Both Cough and sputum n (%) | 97 (33.6%) | 2 (7.7%) | 71 (33.5%) | 24 (47.1%) |
Pre-bronchodilator | ||||
FVC L | 3.9 ± 0.9 | 3.7 ± 0.8 | 4.0 ± 0.9 | 3.9 ± 0.9 |
FVC % predicted | 96.2 ± 12.5 | 102.6 ± 13.4 | 96.6 ± 11.5 | 90.9 ± 14.1 |
FEV1 L | 3.0 ± 0.8 | 3.2 ± 0.7 | 3.2 ± 0.8 | 2.5 ± 0.7 |
FEV1 % predicted | 90.8 ± 16.9 | 108.1 ± 13.5 | 94.6 ± 13.0 | 70.4 ± 15.5 |
FEV1/FVC % | 76.8 ± 9.3 | 81.4 ± 5.3 | 79.5 ± 6.1 | 62.9 ± 9.4 |
Post-bronchodilator | ||||
FVC L | 4.0 ± 1.0 | 3.7 ± 0.8 | 4.0 ± 1.0 | 4.1 ± 1.0 |
FVC % predicted | 96.7 ± 12.6 | 105.0 ± 9.9 | 96.5 ± 12.4 | 95.2 ± 13.4 |
FEV1 L | 3.1 ± 0.8 | 3.1 ± 0.6 | 3.3 ± 0.8 | 2.6 ± 0.7 |
FEV1 % predicted | 93.3 ± 16.3 | 110.6 ± 13.6 | 96.8 ± 12.8 | 74.3 ± 14.8 |
FEV1/FVC % | 78.7 ± 9.3 | 84.3 ± 5.3 | 81.6 ± 5.5 | 62.9 ± 7.7 |